Atom Investors’s Humacyte HUMA Stock Holding History

Atom Investors’s Portfolio HUMA Stock Details HUMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-25,866	Closed	-$24.8K	–	742
2025 Q4	$24.8K	Buy	+25,866	New	+$36.6K	﹤0.01%	553
2025 Q3	–	Sell	-11,124	Closed	-$23.2K	–	706
2025 Q2	$23.2K	Buy	+11,124	New	+$21.4K	﹤0.01%	585

Other funds holding HUMA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Antipodes Partners Royal Exchange, Australia $5.19B AUM 36.17% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Atom Investors's HUMA Position: Q1 2026 in Review

Atom Investors sold out of Humacyte (HUMA) in Q1 2026, closing a stake of 25,866 shares — an estimated $24.8K sold.

Atom Investors first reported a position in HUMA in Q2 2025 and held it in 2 quarters. The position peaked at $24.8K in Q4 2025. 158 funds tracked by Wall St. Rank hold HUMA as of Q1 2026.

Atom Investors reported no remaining Humacyte position as of Q1 2026 after selling out during the quarter.
Atom Investors sold 25,866 Humacyte shares in Q1 2026, an estimated $24.8K.
Atom Investors first reported a position in Humacyte in Q2 2025 and held it in 2 quarters.
Atom Investors's Humacyte position peaked at $24.8K in Q4 2025.
158 funds tracked by Wall St. Rank held Humacyte as of Q1 2026.

Based on Atom Investors's 13F filing for Q1 2026, filed 15 May 2026.